Spero Therapeutics (NASDAQ:SPRO) Posts Earnings Results, Misses Expectations By $0.03 EPS

Spero Therapeutics (NASDAQ:SPRO) released its quarterly earnings data on Thursday. The company reported ($0.38) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03), Zacks reports. Spero Therapeutics had a net margin of 3.30% and a return on equity of 4.03%.

Spero Therapeutics Trading Down 3.4 %

Shares of NASDAQ:SPRO traded down $0.03 during trading on Thursday, hitting $0.86. 82,304 shares of the company’s stock traded hands, compared to its average volume of 190,327. The company has a 50-day moving average price of $0.82 and a 200-day moving average price of $1.06. Spero Therapeutics has a 52 week low of $0.73 and a 52 week high of $1.81. The company has a market cap of $46.89 million, a price-to-earnings ratio of 12.29 and a beta of 0.68.

Insiders Place Their Bets

In other news, CEO Sath Shukla sold 155,333 shares of the stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $0.78, for a total transaction of $121,159.74. Following the completion of the sale, the chief executive officer now owns 1,736,883 shares of the company’s stock, valued at $1,354,768.74. This represents a 8.21 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ankit Mahadevia sold 69,219 shares of the firm’s stock in a transaction on Wednesday, February 5th. The stock was sold at an average price of $0.78, for a total transaction of $53,990.82. Following the sale, the director now owns 689,866 shares in the company, valued at approximately $538,095.48. The trade was a 9.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 245,241 shares of company stock worth $191,288. Company insiders own 4.52% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently issued reports on SPRO. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Spero Therapeutics in a research report on Thursday, January 30th. Evercore ISI downgraded shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 target price for the company. in a research note on Friday, December 20th.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.